在研适应症：人类偏肺病毒感染

Human metapneumovirus (hMPV) is a leading cause of acute lower respiratory tract infections in high-risk populations， yet there are no vaccines or anti-viral therapies approved for the prevention or treatment of hMPV-associated disease. Here， monotherapy with neutralizing antibodies targeting three distinct antigenic sites provided robust protection against lower respiratory tract infection in a small animal model. This study provides promising monoclonal antibody candidates for passive immunoprophylaxis and informs the rational design of hMPV vaccine immunogens. ， highly potent broadly neutralizing antibodies that recognize pre-fusion-specific epitopes and structurally characterized an antibody that targets a site of vulnerability at the pre-fusion F trimer apex. Additionally， we identified rare。

we used a high-throughput single-cell technology to interrogate memory B cell responses to the hMPV fusion (F) glycoprotein in young adult and elderly donors. Across all donors， the neutralizing antibody response was primarily directed to epitopes expressed on both pre- and post-fusion F conformations. However，。